

UC Irvine

UC Irvine Previously Published Works

Title

DDEL-06PRELIMINARY SAFETY OF TOCA 511, A RETROVIRAL REPLICATING VECTOR, IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA ACROSS THREE SEPARATE PHASE 1 STUDIES

Permalink

<https://escholarship.org/uc/item/8mg9z4jn>

Journal

Neuro-Oncology, 17(suppl_5)

ISSN

1522-8517

Authors

Kalkanis, Steven N
Aghi, Manish K
Cloughsy, Timothy F
et al.

Publication Date

2015-11-01

DOI

10.1093/neuonc/nov212.06

Peer reviewed

Abstracts

DDDEL-06. PRELIMINARY SAFETY OF TOCA 511, A RETROVIRAL REPLICATING VECTOR, IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA ACROSS THREE SEPARATE PHASE 1 STUDIES

Steven N. Kalkanis¹, Manish K. Aghi², Timothy F. Cloughesy³, George Kaptain⁴, Jana Portnow⁵, Michael A. Vogelbaum⁶, Santosh Kesari⁷, Tom Mikkelsen¹, J. Bradley Elder⁸, Clark C. Chen⁷, David Piccioni⁷, David Baskin⁹, Jonathan Engh¹⁰, Daniella Bota¹¹, E. Antonio Chiocca⁸, Greg Foltz¹⁴, Derek Ostertag¹³, Dawn Gammon¹³, Andreas Niethammer¹³, and Joseph Landolfi¹²; ¹Henry Ford Health System, Detroit, MI, USA; ²University of California Neurologic Surgery San Francisco, San Francisco, CA, USA; ³David Geffen School of Medicine, UCLA, Los Angeles, CA, USA; ⁴John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; ⁵City of Hope, Duarte, CA, USA; ⁶Cleveland Clinic Foundation, Cleveland, OH, USA; ⁷Moore's Cancer Center, Department of Neurosciences, UCSD, San Diego, CA, USA; ⁸Ohio State University Wexner Medical Center, Columbus, OH, USA; ⁹Weill Cornell Medical College, Houston Methodist Hospital, Houston, TX, USA; ¹⁰University of Pittsburgh Medical Center, Pittsburgh, PA, USA; ¹¹University of California, Irvine Medical Center, Irvine, CA, USA; ¹²New Jersey Neuroscience Institute, JFK Medical Center, Edison, NJ, USA; ¹³Tocagen, Inc, San Diego, CA, USA; ¹⁴Swedish Neuroscience Institute, Seattle, WA, USA

High grade glioma (HGG) remains resistant to standard therapies with survival ranging from 7.2-8.1 months. Two Phase 1 clinical studies using a retroviral replicating vector (RRV), Toca 511, in combination with oral Toca FC (extended-release 5-FC) are ongoing to evaluate intracranial delivery of Toca 511 in patients with recurrent HGG. Patients were treated either by administering Toca 511 via intratumoral injection by biopsy needle or convection-enhanced delivery (CED) (NCT01156584), or by injection into the resection cavity wall (NCT01470794). The total safety population included 82 patients. The safety profile was favorable with only 3.7% patients experiencing a treatment related SAE and 1 patient discontinuing treatment due to toxicity (rash). A total of 59 patients who were efficacy evaluable (received Toca 511 and at least one dose of Toca FC) and excluding patients with non-biopsy needle delivery had a mOS of 13.8 months (95% CI 10.8,16.9). Cox-regression was used to examine factors associated with survival outcome. Baseline factors included for univariate analysis were tumor grade (III vs IV), number of recurrences (≤ 2 vs > 2), gender, age (≤ 55 vs > 55), longest diameter of cancerous lesion (continuous), daily dose of Toca FC (≥ 170 mg/kg vs < 170 mg/kg), extent of primary resection (gross-total vs subtotal), KPS (≤ 80 vs > 80), time between Toca 511 and Toca FC (weeks), and respective study participation (NCT01156584 vs NCT01470794). Of these, tumor grade, number of recurrences, gender and lesion diameter were included for multivariate analysis based on a p value > 0.2 in the univariate analysis. Based on the multivariate analysis, the only statistically significant positive prognostic factor was the category of number of recurrences. Excluding patients with > 2 recurrences, the observed median overall survival (mOS) is 14 months (95% CI 11.15, 23.36), comparing favorably to historical benchmarks. 60% and 24.7% of patients were alive after 12 and 24 months, respectively.